Sanofi to Cut US Price of Its Most-Prescribed Insulin by 78%

France Nouvelles Nouvelles

Sanofi to Cut US Price of Its Most-Prescribed Insulin by 78%
France Dernières Nouvelles,France Actualités
  • 📰 Medscape
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 55%

Sanofi to cut US price of its most-prescribed insulin by 78%. MedTwitter diabetes

- Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co.

In addition to Lantus, Sanofi said it will cut by 70% the list price for its fast-acting insulin, Apidra. The company said it has a 40% share of the U.S. long-acting insulin market and a 4% share of the rapid-acting market. Most Americans with insurance do not regularly pay list price for insulin, but they may have an insurance co-pay based on the drug's list price or pay full price up to a certain amount of money spent.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Medscape /  🏆 386. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Lire la suite »

Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Lire la suite »

Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%French drugmaker Sanofi SA said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big diabetes drugmakers facing pressure over high costs.
Lire la suite »

Sanofi Is Latest Drugmaker to Cut Insulin PricesSanofi Is Latest Drugmaker to Cut Insulin PricesSanofi is planning to cut the U.S. price of its most-prescribed insulin by 78% and cap monthly out-of-pocket costs at $35 for people who have private insurance. CNBC
Lire la suite »

Sanofi is the latest insulin maker to announce price capSanofi is the latest insulin maker to announce price capSanofi joins Eli Lilly and Novo Nordisk to cap insulin prices. President Joe Biden still wants Congress to enact limits. MORE ⬇️
Lire la suite »

Mission Valley River Crossings Closed After Storm Drenches San Diego; Flooded SR-78 Closed WestboundMission Valley River Crossings Closed After Storm Drenches San Diego; Flooded SR-78 Closed WestboundNon-stop overnight rain from the latest in a series of atmospheric river storms to reach San Diego County flooded streets, prompted dozens of crashes on rain-slicked roadways and downed trees across the county Wednesday.
Lire la suite »



Render Time: 2025-03-05 05:05:00